We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Anika Therapeutics (ANIK - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Anika Therapeutics is one of 1181 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Anika Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANIK's full-year earnings has moved 41.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ANIK has gained about 4.7% so far this year. Meanwhile, the Medical sector has returned an average of -16.1% on a year-to-date basis. As we can see, Anika Therapeutics is performing better than its sector in the calendar year.
Another stock in the Medical sector, Achilles Therapeutics PLC Sponsored ADR , has outperformed the sector so far this year. The stock's year-to-date return is 31.1%.
For Achilles Therapeutics PLC Sponsored ADR, the consensus EPS estimate for the current year has increased 1.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Anika Therapeutics belongs to the Medical - Biomedical and Genetics industry, a group that includes 559 individual companies and currently sits at #69 in the Zacks Industry Rank. On average, this group has lost an average of 17.7% so far this year, meaning that ANIK is performing better in terms of year-to-date returns. Achilles Therapeutics PLC Sponsored ADR is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Anika Therapeutics and Achilles Therapeutics PLC Sponsored ADR. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Anika Therapeutics (ANIK - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Anika Therapeutics is one of 1181 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Anika Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANIK's full-year earnings has moved 41.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ANIK has gained about 4.7% so far this year. Meanwhile, the Medical sector has returned an average of -16.1% on a year-to-date basis. As we can see, Anika Therapeutics is performing better than its sector in the calendar year.
Another stock in the Medical sector, Achilles Therapeutics PLC Sponsored ADR , has outperformed the sector so far this year. The stock's year-to-date return is 31.1%.
For Achilles Therapeutics PLC Sponsored ADR, the consensus EPS estimate for the current year has increased 1.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Anika Therapeutics belongs to the Medical - Biomedical and Genetics industry, a group that includes 559 individual companies and currently sits at #69 in the Zacks Industry Rank. On average, this group has lost an average of 17.7% so far this year, meaning that ANIK is performing better in terms of year-to-date returns. Achilles Therapeutics PLC Sponsored ADR is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Anika Therapeutics and Achilles Therapeutics PLC Sponsored ADR. These stocks will be looking to continue their solid performance.